TreatmentWith theDipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized,

Chronic kidney disease (CKD) is fre-quently comorbid with type 2 diabetes, and glucose-lowering treatment options are limited for such patients (1). We in-vestigated the efficacy and safety of linagliptin, a dipeptidyl peptidase-4 in-hibitor, in type 2 diabetic patients with moderate to severe renal impairment and insufficient glycemic control. This randomized, double-blind, parallel-group clinical trial comprised a 12-week, placebo-controlled phase followed by a 40-week, active-controlled extension. The study was conducted between 1